Helpful resources for your practice
Get materials and forms designed with information about accessing, acquiring, and administering YEZTUGO.
HCP resources
Patient resources
Gilead medical information
A resource for US healthcare professionals with scientific and clinical information on Gilead products.
Stay up to date on YEZTUGO
Register to receive emails about YEZTUGO efficacy and safety, prescribing YEZTUGO, or to learn more about the administration process. Please fill out the form below.
*Required field.
FAQs
bHIV is an estimate of HIV incidence in populations enrolled in the study if they were not on PrEP. bHIV was used as a comparator in lieu of a placebo arm for ethical reasons. See more about the innovative study design of YEZTUGO.
PURPOSE 1 included cisgender adolescent girls and young women aged 16 to 25 years with likelihood of acquiring HIV (had sexual encounters with male partners without recent HIV testing and had unknown HIV status) and were not on PrEP.1,3
PURPOSE 2 included cisgender men, transgender women, transgender men, and nonbinary individuals aged 16+ years with likelihood of acquiring HIV (had condomless sex with male partners, no recent HIV testing, and had unknown HIV status) and were not on PrEP.2,3
At the time of the primary analysis, there were 2 incident HIV infections among participants in the YEZTUGO arm, both with N74D resistance-associated capsid substitutions. This resistance-associated substitution does not impact DHHS-recommended initial regimens for HIV treatment, which typically include a combination of INSTI with NRTI.
On Day 1 of initiation, you’ll give the individual 2 injections into the appropriate injection sites and 2 YEZTUGO tablets for them to take that day in your office, then 2 tablets to be taken at home the next day.
The continuation dosing is 2 injections every 6 months from the date of the last injection, unless the injection schedule is interrupted. Review dosing.
The protocol varies depending on whether there are delayed or missed doses. See dosing details.
YEZTUGO comes as a vial and must be drawn into the provided syringes before injection in office. See administration details.
There are no specific requirements to rotate injection sites every 6 months, but each of the 2 injections must be at least 4 inches apart. The administrator may determine which injection sites are clinically appropriate. See administration details.
Yes. Gilead offers daily PrEP options. Explore one option here.
DHHS=US Department of Health and Human Services; INSTI=integrase strand transfer inhibitor; NRTI=nucleoside/nucleotide reverse transcriptase inhibitor.
Important Safety Information
BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF YEZTUGO IN UNDIAGNOSED HIV-1 INFECTION
- Individuals must be tested for HIV-1 infection prior to initiating YEZTUGO, and with each subsequent injection of YEZTUGO, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of YEZTUGO by individuals with undiagnosed HIV-1 infection. Do not initiate YEZTUGO unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving YEZTUGO must transition to a complete HIV-1 treatment regimen.
Contraindications
- YEZTUGO is contraindicated in individuals with unknown or positive HIV-1 status.
Warnings and precautions
- Comprehensive risk management:
- Use YEZTUGO to reduce the risk of HIV-1 acquisition as part of a comprehensive prevention strategy including adherence to the administration schedule and safer sex practices, including condoms, to reduce the risk of sexually transmitted infections (STIs).
- HIV-1 acquisition risk includes behavioral, biological, or epidemiologic factors including, but not limited to, condomless sex, past or present STIs, self-identified HIV risk, having sexual partners of unknown HIV-1 viremic status, or sexual activity in a high-prevalence area or network. Counsel individuals on the use of other prevention methods to help reduce their risk.
- Use YEZTUGO only in individuals confirmed to be HIV-1 negative. Evaluate for current or recent signs or symptoms consistent with HIV-1 infection. Confirm HIV-1 negative status prior to initiating, prior to each subsequent injection, and as clinically appropriate.
- Potential risk of resistance:
- There is a potential risk of developing resistance to YEZTUGO if an individual acquires HIV-1 before or when receiving YEZTUGO, or following discontinuation. HIV-1 resistance substitutions may emerge in individuals with undiagnosed HIV-1 infection taking only YEZTUGO, because YEZTUGO alone is not a complete regimen for HIV-1 treatment.
- To minimize this risk, it is essential to test before each injection and additionally as clinically appropriate. Individuals confirmed to have HIV-1 must immediately begin a complete HIV-1 treatment regimen.
- Alternative forms of PrEP should be considered after discontinuation of YEZTUGO for those who are at continuing risk of HIV-1 acquisition and should be initiated within 28 weeks of the last YEZTUGO injection.
- Long-acting properties and potential associated risks:
- Residual concentrations of YEZTUGO may remain in systemic circulation for up to 12 months or longer after the last injection.
- Select individuals who agree to the required injection dosing schedule because nonadherence or missed doses could lead to HIV-1 acquisition and development of resistance.
- Serious injection site reactions: Improper administration (intradermal injection) has been associated with serious injection site reactions, including necrosis and ulcer. Only administer YEZTUGO subcutaneously.
Adverse reactions
- Most common adverse reactions (≥5%) in YEZTUGO clinical trials were injection site reactions, headache, and nausea.
Drug interactions
- Strong or moderate CYP3A inducers may significantly decrease YEZTUGO concentrations. Dosage modifications are recommended when initiating these inducers.
- It is not recommended to use YEZTUGO with combined P-gp, UGT1A1, and strong CYP3A inhibitors.
- Coadministration of YEZTUGO with sensitive substrates of CYP3A or P-gp may increase their concentrations and result in the increased risk of their adverse events. YEZTUGO may increase the exposure of drugs primarily metabolized by CYP3A initiated within 9 months after the last injection of YEZTUGO.
Dosage and administration
- HIV screening: Test for HIV-1 infection prior to initiating, prior to each subsequent injection, and as clinically appropriate using an approved or cleared test for the diagnosis of acute or primary HIV-1 infection.
- Dosage: Initiation dosing (injections and tablets) followed by once-every-6-months continuation injection dosing. Tablets may be taken with or without food.
- Initiation: Day 1: 927 mg by subcutaneous injection (2 x 1.5-mL injections) and 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally.
- Continuation: 927 mg by subcutaneous injection every 6 months (26 weeks) from date of last injection ±2 weeks.
- Anticipated delayed injections: If scheduled 6-month injection is anticipated to be delayed by more than 2 weeks, YEZTUGO tablets may be taken on an interim basis (for up to 6 months) until injections resume. Dosage is 300 mg orally (1 x 300-mg tablet) once every 7 days. Resume continuation injections within 7 days of the last oral dose.
- Missed injections: If more than 28 weeks have elapsed since the last injection and YEZTUGO tablets have not been taken, restart with initiation dosing if clinically appropriate.
- Dosage modifications of YEZTUGO are recommended when initiating with strong or moderate CYP3A inducers. Consult the full Prescribing Information for recommendations.
Indication
YEZTUGO is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (≥35 kg) who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO.
Please see full Prescribing Information for YEZTUGO, including BOXED WARNING.
References:
- Bekker LG, Das M, Abdool Karim Q, et al; PURPOSE 1 study team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179-1192.
- Kelley CF, Acevedo-Quiñones M, Agwu AL, et al; PURPOSE 2 study team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392(13):1261-1276.
- YEZTUGO. Prescribing information. Gilead Sciences, Inc.; 2025.
- Department of Health and Human Services. Guidelines for use of antiretroviral agents in adults and adolescents with HIV. Clinical info. Updated September 12, 2024. Accessed May 13, 2025. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf